Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 2
2019 1
2020 1
2021 2
2022 8
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC. Li L, et al. Among authors: korentzelos d. Sci Signal. 2017 May 23;10(480):eaam7479. doi: 10.1126/scisignal.aam7479. Sci Signal. 2017. PMID: 28536297 Free PMC article.
Renal Sarcoma: A Population-Based Study.
Alevizakos M, Gaitanidis A, Korentzelos D, Basourakos SP, Burgess M. Alevizakos M, et al. Among authors: korentzelos d. Clin Genitourin Cancer. 2023 Feb;21(1):155-161. doi: 10.1016/j.clgc.2022.07.012. Epub 2022 Jul 30. Clin Genitourin Cancer. 2023. PMID: 36045013
Development and validation of a prognostic nomogram for overall and disease-specific survival in patients with sarcomatoid urothelial carcinoma.
Diamantopoulos LN, Makrakis D, Korentzelos D, Alevizakos M, Wright JL, Grivas P, Bountziouka V, Vadikolias K, Lambropoulou M, Tripsianis G. Diamantopoulos LN, et al. Among authors: korentzelos d. Urol Oncol. 2023 Jun;41(6):296.e17-296.e28. doi: 10.1016/j.urolonc.2023.01.019. Epub 2023 Mar 15. Urol Oncol. 2023. PMID: 36931981 Clinical Trial.
Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.
Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone N, Troncoso P, Thompson TC. Zhang W, et al. Among authors: korentzelos d. Clin Cancer Res. 2018 Feb 1;24(3):696-707. doi: 10.1158/1078-0432.CCR-17-1872. Epub 2017 Nov 14. Clin Cancer Res. 2018. PMID: 29138344 Free PMC article.
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, Manyam GC, Korentzelos D, Park S, Tang Z, Wu C, Dong Z, Sigouros M, Sboner A, Beltran H, Chen Y, Corn PG, Tetzlaff MT, Troncoso P, Broom B, Thompson TC. Liu B, et al. Among authors: korentzelos d. Clin Cancer Res. 2019 Nov 15;25(22):6839-6851. doi: 10.1158/1078-0432.CCR-19-0317. Epub 2019 Aug 22. Clin Cancer Res. 2019. PMID: 31439587 Free PMC article.
16 results